Thermo Fisher Scientific Opens Ultra-Cold Facility in the Netherlands to Accelerate Advanced Therapies

With its new facility in Bleiswijk, the American company is meeting global demand for clinical trials innovation and biorepository storage solutions 

U.S.-based Thermo Fisher Scientific, a life science and clinical research company, has opened a new clinical and commercial ultra-cold facility for the EU in the Netherlands. The company’s expansion in the Dutch life sciences and health ecosystem will enable it to grow its clinical trial network in Europe and accelerate the development of advanced therapies. Certified according to current good manufacturing practice (cGMP), the new facility exemplifies the Netherlands’ cutting-edge smart logistics capabilities. 

“The opening of this cutting-edge facility supporting the development of cell and gene therapies and other biologics, coupled with our proven track record in managing valuable materials, places us in an unmatched position to help our global clients develop innovative therapies,” stated Molly Flick, vice president and general manager of bioservices & specialty logistics at Thermo Fisher Scientific.  

Thermo Fisher already has a large footprint in the Netherlands: the company has developed strong relationships with numerous Dutch health & knowledge institutions and operates across 11 Dutch locations, including its existing logistics operations in Bleiswijk, which now features the new facility.

Joining a connected ecosystem of life sciences and health innovators 

Thermo Fisher is dedicated to making the world healthier, cleaner and safer – a mission that aligns with the Netherlands’ Top Sector Life Sciences & Health, also known as Health~Holland. With its expansion in the Netherlands, Thermo Fisher aims to meet the growing demands of cell and gene therapy clinical trials in Europe and beyond. As a hotspot for clinical research and cell and gene therapy, the Netherlands is the ideal place for Thermo Fisher to build its network in these fields. 

The company’s new facility will provide pharma and biopharma customers with tailored, end-to-end support throughout the clinical supply chain for high-value therapies, including cell and gene therapies, biologics, antibodies and vaccines. 

Spread across 5,000 square meters, the Bleiswijk facility enables customers to meet clinical trial requirements regardless of scale or phase. The company will leverage the Netherlands’ highly skilled and talented local workforce to partner with new and emerging biotech and established pharmaceutical companies. 

A sustainable site for state-of-the-art supply chain solutions 

Thermo Fisher’s facility is one example of how the Netherlands offers companies fertile ground to carry out their mission of delivering innovative logistics solutions while crafting a greener future. Leveraging its new location just 30 minutes from Amsterdam, the company plans to build on its market leadership and global CDMO capabilities in bioservices and specialty logistics services, including biorepository solutions and critical material storage. 

The Bleiswijk site is designed to use 15% solar power and operate completely gas-free, provide sustainable heating and cooling with eco-friendly electric heat pumps, and use ultramodern heat recovery technology. It illuminates Thermo Fisher’s commitment to sustainability and its global goal of achieving net-zero emissions by 2050.  

About Thermo Fisher Scientific 

Based in Massachusetts, Thermo Fisher Scientific Inc. assists its customers through accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics, the development and manufacture of life-changing therapies, and more. The company delivers a combination of innovative technologies, purchasing convenience and pharmaceutical services to customers around the world.  

Source: Thermo Fisher Scientific 

18 July 2024